Thompson on user fees
This article was originally published in The Gray Sheet
Executive Summary
Additional Medical Device User Fee & Modernization Act funds are forthcoming, HHS Secretary Tommy Thompson assures FDA Science Forum attendees April 24 in Washington, D.C. Responding to an audience query about the role of the Office of Management & Budget in device appropriations, Thompson reported that FDA Commissioner Mark McClellan "advanced the budget with the money in, and we advanced it to OMB. I didn't realize that in America we had a 'Super God' until I came to Washington, D.C., and I found out [it] is OMB. Congress is going to respond.... We have to work within the guidelines with OMB, [but] at the end of the day...I am absolutely certain there's going to be some additional money" for devices. Industry is seeking a $28.5 mil. increase in the FY 2004 FDA budget to sustain the user-fee program (1"The Gray Sheet" April 21, 2003, In Brief)...
You may also be interested in...
FDA FY 2004 approps
AdvaMed June 18 "fly-in" will bring member CEOs to Congress to advocate additional funds for device user fee program. On that day, AdvaMed plans to unveil the Senate Medical Technology Caucus. Regarding user fees, an April 11 letter from Senate HELP Committee Democrats to Senate Appropriations/Ag Subcommittee Chairman Robert Bennett (R-Utah) seeks a $28.5 mil. increase in the FY 2004 FDA budget to sustain the program and help the agency meet performance goals. Bennett is expected to meet with individual device execs in May...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.